Flot.bio x Philip Hemme

Flot.bio
  • ٠٫٠ (٠)
  • علوم حياة
  • يتم التحديث شهريًا

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

  1. Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London Biotech Startups | E38

    ٢ سبتمبر

    Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London Biotech Startups | E38

    We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer. The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024. Robin outlines Myricx’s journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him. -------------------- This episode is sponsored by Kadans. Learn more about Kadans’ London Innovation Centre where life sciences companies grow from start-up to global player: https://bit.ly/kadans-myricxbio -------------------- ⭐️ ABOUT THE SPEAKER Robin kicked off his Myricx experience as chief development officer in November 2019, before rising to the CEO seat in August 2022. Before this, he was VP of drug discovery at Astex Therapeutics, before spending more than a decade in research executive roles at GSK. ending up as SVP Drug Design and Selection. 🔗 LINKS MENTIONED - Myricx Bio’s website: (https://tiltbio.com/)https://myricxbio.com/- Myrcix Bio’s Series A round: (https://tiltbio.com/userassets/uploads/2025/05/TILT-Series-B-press-release-May-2025.pdf)https://myricxbio.com/myricx-bio-announces-90m-114m-series-a-financing-to-advance-its-novel-nmti-adc-therapeutics-into-clinical-development/- A winding road – the many adventures of a promising ADC - Cancer Research UK: https://news.cancerresearchuk.org/2024/07/09/a-winding-road-the-many-adventures-of-a-promising-adc/- Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19: https://flot.bio/episode/dominik-schumacher-tubulis/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/robin-carr-myricx-bio-adc/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro[00:02:43] Navigating biotech networking[00:07:30] Myricx’s Series A and transformation[00:10:45] The pivot to ADCs[00:22:10] NMT ADCs in cancer[00:32:09] The big pharma to biotech leap[00:42:39] ADCs in Europe, the US and Asia[00:46:17] ADCs are a booming market[00:52:35] Quick-fire questions

    ٥٨ من الدقائق
  2. Aino Kalervo, TILT Biotherapeutics 🇫🇮 | Immunotherapy, Oncolytic Virus | E37 [Sponsored]

    ١٤ يوليو

    Aino Kalervo, TILT Biotherapeutics 🇫🇮 | Immunotherapy, Oncolytic Virus | E37 [Sponsored]

    We dive into the world of cutting-edge cancer treatments with Aino Kalervo, Chief Operating Officer of TILT Biotherapeutics and occasional tennis legend in her spare time.TILT recently closed a $25M series B round, backed by leading Finnish investors, to finance the clinical development of its oncolytic virus candidate to supercharge cancer immunotherapies.We also explore the challenging space of oncolytic viruses and the untapped potential of biotech innovation in Finland.______For transparency, this episode has been sponsored by TILT.______⭐️ ABOUT THE SPEAKERAino Kalervo is the Chief Operating Officer of TILT Biotherapeutics, responsible for fundraising and business development. She has also served as the president of TILT’s US affiliate since 2022. Prior to joining TILT, she worked for Sanofi and the French therapeutic vaccine company Theravectys.🔗 LINKS MENTIONED- TILT Biotherapeutics’ website: https://tiltbio.com/- TILT’s Series B round: https://tiltbio.com/userassets/uploads/2025/05/TILT-Series-B-press-release-May-2025.pdf- Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21 - Flot.bio: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/aino-kalervo-tilt-immunotherapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:44] Inside TILT’s $25M series B round[00:04:04] Multi-action oncolytic viruses[00:10:54] Learning from their peers[00:14:07] Phase 1 for melanoma[00:21:14] Collaborations and competitors[00:23:17] From Helsinki to global trials[00:33:03] Finland’s biotech ecosystem[00:39:00] Aino Kalervo’s personal path[00:45:43] Quickfire

    ٤٩ من الدقائق
  3. Renee Aguiar-Lucander, Hansa Biopharma 🇸🇪 | Immunology, Gene therapy | E36

    ٣٠ يونيو

    Renee Aguiar-Lucander, Hansa Biopharma 🇸🇪 | Immunology, Gene therapy | E36

    Fresh after leading Calliditas Therapeutics through a $1.1B acquisition, Renee Aguiar-Lucander takes us through her new CEO role at Hansa Biopharma 🇸🇪.We learn how Hansa is commercialising Idefirix, its lead product for improving outcomes in kidney transplantation. We also cover the hot area of immunology, the behind-the-scenes story behind Calliditas’ takeover and the complex world of biotech financing.-----Launching a biotech startup? Grab your Biotech Starter Kit through Merck’s New Lab Starter Program and get the tools and support you need from day one: https://bit.ly/biotech-starter-kit----⭐️ ABOUT THE SPEAKERRenee Aguiar-Lucander became the CEO of Hansa Biopharma in April 2025 after a seven-year tenure as CEO of Calliditas Therapeutics, which Asahi Kasei Corporation acquired in September 2024. Before her CEO roles, she also had a long career in healthcare investments with senior roles in funds including Omega Fund Management and 3i Group.🔗 LINKS MENTIONED- Hansa Biopharma’s Interim Report Q1 April 2025: https://www.hansabiopharma.com/files/Main/1219/4138498/20250423-hnsa--q1-2025-quarterly-report-eng.pdf- The acquisition announcement of Calliditas Therapeutics by Asahi Kasei: https://asahi-kasei.eu/acquire-calliditas-therapeutics-ab/- Hansa Biopharma’s website: https://www.hansabiopharma.com/- Marc de Garidel, Abivax | How to make two Billion-dollar exits ("smoothly") | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/- Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31: https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/renee-aguiar-lucander-hansa/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:18] Joining Hansa Biopharma- [00:03:23] How Idefirix works- [00:06:45] Commercialization and competition- [00:15:24] Navigating biotech finances- [00:19:51] Lessons from Calliditas’ exit- [00:27:11] Sofinnova and European crossover funds- [00:41:23] Immunology is hot- [00:44:04] Financing to management- [00:47:54] Women leading biotech- [00:50:20] Quickfire

    ٥٤ من الدقائق
  4. Stephane Bancel, Moderna | mRNA Therapeutics, Boston Biotech Mafia, AI Biotech | E35

    ٢٣ يونيو

    Stephane Bancel, Moderna | mRNA Therapeutics, Boston Biotech Mafia, AI Biotech | E35

    We’re with Stephane Bancel, CEO of the US mRNA giant Moderna. The company’s 15-year trajectory has taken it from the startup seed stage to a commercial heavyweight with three mRNA-based products in the market 🧬 We go in-depth into Stephane’s leadership style and background before delving into Moderna’s research and the evolution of the mRNA space. ⭐️ ABOUT THE SPEAKER Stéphane Bancel joined mRNA therapeutics company Moderna as CEO in 2011 and led its efforts to develop a commercial COVID-19 vaccine during the global pandemic in 2020. Prior to this, he held senior roles in the pharmaceutical and biotech sectors, including CEO of bioMérieux and Country Manager for Belgium at Eli Lilly. 🔗 LINKS MENTIONED - Moderna website: https://www.modernatx.com/ - Moderna partners with OpenAI: http://investors.modernatx.com/news/news-details/2024/Moderna-and-OpenAI-Collaborate-To-Advance-mRNA-Medicine/default.aspx - Ingmar Hoerr, CureVac | Founding a €20B Biotech | E03: https://flot.bio/episode/ingmar-hoerr-curevac-founding-a-20b-biotech-and-almost-dying-as-ceo/ - Harpreet Singh, Immatics 🇩🇪 | PRAME, TCR Based Therapeutics | E20:https://flot.bio/episode/harpreet-singh-immatics/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/stephane-bancel-moderna-mrna/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:01:44] Building an effective team - [00:04:10] The Boston biotech mafia - [00:09:10] mRNA as a platform - [00:09:10] mRNA as a platform - [00:12:25] The transition to entrepreneurship - [00:27:31] mRNA pionners - [00:36:32] Innovation at scale - [00:47:12] Beyond vaccines - [00:53:38] AI everywhere - [00:55:16] Quickfire

    ٥٩ من الدقائق
  5. Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34

    ٢٦ مايو

    Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34

    We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of Ohtuvayre, Verona’s drug. We also discuss the British roots of the company and why execution is the most important in biotech.⭐️ ABOUT THE SPEAKERChris Martin joined Verona Pharma as their COO in 2020. He’s at the helm of Verona’s commercial strategy, driving the company’s progress in respiratory medicine. Before Verona, Chris played a key role as Executive Director of Marketing at SK Life Science, where he helped launch the CNS treatment XCOPRI® (cenobamate tablets). He also led the marketing efforts at Cempra, guiding the launch of their first product, and spent a decade at Salix Pharmaceuticals, where he led the Xifaxan® marketing team through its acquisition by Valeant Pharmaceuticals.🔗 LINKS MENTIONED- Verona Pharma’s corporate presentation: https://www.veronapharma.com/wp-content/uploads/2025/04/VRNA-Presentation-May-2025.pdf- Verona website: [http://veronapharma.com](http://veronapharma.com/)- Ohtuvayre website: [http://ohtuvayre.com](http://ohtuvayre.com/)- Q1 2025 results: https://www.veronapharma.com/news/verona-pharma-reports-first-quarter-2025-financial-results-and-provides-corporate-update/- Royalty pharma website: [https://www.royaltypharma.com](https://www.royaltypharma.com/)- Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy | E22: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/- Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14: https://flot.bio/episode/bahija-jallal-immunocore/ - The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/ 📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/chris-martin-verona-pharma-copd/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:04] Commercial rollout of Ohtuvayre- [00:06:42] Fierce competition in COPD- [00:10:34] UK origins of Verona Pharma- [00:21:24] Strong Clinical data for Chronic Disease Patients- [00:26:01] Reaching Profitability for Verona Pharma- [00:30:58] Chris Martin Joining Verona Pharma- [00:34:51] Execution is Key to Success in Biotech- [00:42:48] How to get to the top in Biotech without a background in science- [00:46:33] Royalty model in Biotech- Quickfire

    ٥٥ من الدقائق
  6. Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 [Sponsored]

    ٥ مايو

    Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 [Sponsored]

    We’re online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.🔗 LINKS MENTIONED- CUTISS Homepage (technology, about us): [https://cutiss.swiss](https://cutiss.swiss/)- CUTISS Deck Series C: https://cutiss.swiss/wp-content/uploads/2025/03/CUTISS-AG-Teaser-Q1-2025_Series-C.pdf- Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/- Ingmar Hoerr, CureVac | Founding a €20B Biotech | E03: https://flot.bio/episode/ingmar-hoerr-curevac-founding-a-20b-biotech-and-almost-dying-as-ceo/- Giammaria Giuliani profile https://www.forbes.com/profile/giammaria-giuliani/- Hansjorg Wyss profile - [https://en.wikipedia.org/wiki/Hansjörg_Wyss](https://en.wikipedia.org/wiki/Hansj%C3%B6rg_Wyss)📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:41] Story of CUTISS[00:04:47] Positive Phase 2 Data[00:16:03] Raising a Series C[00:26:34] Next steps for CUTISS[00:31:46] Cell Therapy and Tissue Therapy landscape[00:42:36] US Biotech Market[00:45:12] TechBio, Hardware and Automation[00:50:58] Kids preventing burnout[00:54:18] Daniela Marino, Academic and Female Founder[01:01:10] Quickfire

    ١ س ٦ د
  7. Joris Pezzini, Alira Health | Hottest Biotech Insights | E32 [Sponsored]

    ٢٢ أبريل

    Joris Pezzini, Alira Health | Hottest Biotech Insights | E32 [Sponsored]

    We’re in Barcelona 🇪🇸  with Joris Pezzini from Alira Health to discuss the hottest biotech insights right now, including obesity, I&I, radiopharmaceuticals and ADCs. --- This episode is sponsored by Alira Health, an advisor and clinical development partner for life sciences companies. Learn more at https://bit.ly/alirahealth-flotbio-1 --- ⭐️ ABOUT THE SPEAKER Joris Pezzini has been in the biotech world for over 15 years. Before joining Alira Health in 2019, he had worked in some top pharma and biotech companies across the US, UK and France, including UCB, LFB, and Bionest Partners. Through this combo of roles as a Biopharma executive in start-ups, mid-sized, pharma, and consulting firms, Joris has a good eye on the industry with a wealth of experience and knowledge. 🔗 LINKS MENTIONED - Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset: https://www.fiercebiotech.com/biotech/roche-fattens-obesity-pipeline-paying-zealand-165b-upfront-co-develop-amylin-asset - Medicine 3.0: What It Is and Why You Need It - Hone Health: https://honehealth.com/edge/medicine-3-0-peter-attia/ - Why ADCs and Radiopharmaceuticals Are Big Pharma’s New Obsession: https://flot.bio/adcs-radiopharmaceuticals-alira-health/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/joris-pezzini-alira-health-biotech-trend/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:02:17] Hottest biotech industry trends according to Joris Pezzini - [00:11:14] Medicine 3.0 - [00:13:22] ADCs and Radiopharmaceuticals - [00:17:00] The “end” of the blockbuster model - [00:20:35] Challenges to raise money - [00:27:41] Transatlantic & China - [00:33:04] The success story of Alira - [00:44:50] Investing in real-world evidence and AI - [00:48:53] Background in bioprocessing - [00:58:20] Bridging biotech and healthy lifestyle - [01:05:42] Quickfire

    ١ س ١١ د
  8. Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31

    ١٦ أبريل

    Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31

    We’re in Copenhagen 🇩🇰 with Christophe Bourdon, the CEO who turned a 116-year-old biopharma company from the brink of failure to success.We discuss the lessons behind the turnaround, innovation in dermatology, especially biologicals and I&I, and living in eight different countries. ⭐️ ABOUT THE SPEAKER Christophe Bourdon came to be CEO of LEO Pharma in 2022, where he was tasked with the massive assignment of transforming the financially failing company into a success. Luckily, he had gained experience in roles of increasing leadership importance in many EU biotech companies, Sanofi, Amgen, and Alexion, as well as leading the smaller biotech, Orphazyme A/S, as their CEO. No,w Leo Pharma is in the green. 🔗 LINKS MENTIONED - Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/ - Jens Nielsen, BII | How to make translation of life science research work | E12: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/ - On the Origin of Species: Charles Darwin: https://tinyurl.com/2nbhkecs - Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma: https://www.fiercebiotech.com/biotech/gilead-roars-jpm25-250m-upfront-research-deal-leo-pharma - Homepage LEO Pharma, history and pipeline: http://leo-pharma.com/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:54] Turnaround of LEO Pharma [00:08:47] Current products at LEO Pharma [00:17:28] STAT6 Protein Degrader, deal with Gilead [00:23:34] Immunology & Inflammation is hot [00:28:26] Pipeline of LEO Pharma & Dealmaking [00:38:20] Finance & IPO [00:45:03] Living & working in 8 countries [00:48:17] Quickfire

    ٥١ من الدقائق
مشاهدة الكل (٣٨)

حول

Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free. Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.

المعلومات

  • صناع العمل
    Flot.bio
  • سنوات النشاط
    ٢٠٢٣ - ٢٠٢٥
  • الحلقات
    ٣٨
  • التقييم
    ملائم
  • حقوق النشر
    © Flot.bio
  • موقع البرنامج على الويب
    Flot.bio x Philip Hemme

قد يعجبك أيضًا